Contact
Please use this form to send email to PR contact of this press release:
Everest Medicines Announces The China Center for Drug Evaluation, National Medical Products Administration Recommends Breakthrough Therapy Designation for Nefecon for the Treatment of IgA Nephropathy
TO: